Precision BioSciences Inc (DTIL) is a clinical-stage biotechnology company focused on genome editing via its proprietary ARCUS platform. The company has yet to generate product sales revenue, relying primarily on licensing and collaboration proceeds amid substantial operating losses exceeding $45 million in fiscal 2025. Its lead wholly-owned clinical programs target chronic hepatitis B and Duchenne muscular dystrophy, with regulatory progress including FDA Fast Track designation for PBGENE-DMD. Despite promising technology differentiation and partnerships, near-term growth depends on clinical trial advancement and successful capital raises given persistent cash burn and negative operating cash flow. The company faces risks including regulatory complexities, intellectual property challenges, manufacturing dependencies, and funding sustainability.